GI (RTOG 1010): HER2-Overexpressing Esophageal adenocarcinoma
A Randomized Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment o fHER2-Overexpressing Esophageal Adenocarcinoma
Cancer that involves the mid to distal esophagus, and up to 5 cm of the stomach. T1 N1-2, T2-3 N0-1. Must have tissue available for HER2 testing by central pathology. Surgical consult confirming pt can undergo a cruative resection after completion of chemoradiation. Endoscopic ultrasound prior to step 2 registration unless patient is found to have adenopathy per scan(s).